Tislelizumab in Combination With Chemotherapy for Conversion Therapy of Locally Nonresectable ESCC

• Status: Recruiting
• Trial end date: 2022-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a single-arm，open-label study to evaluate the efficacy and safety of tislelizumab plus chemotherapy for conversion therapy of patients with locally nonresectable ESCC.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: The First Affiliated Hospital with Nanjing Medical University
• Treatments: Cisplatin

Criteria

Inclusion Criteria:

1. Aged between 18 and 75 years;

2. Understand the research procedure and content, and voluntarily sign written informed consent;

3. Patients with clinical stage IIA-IIIB esophageal cancer were assessed by endoscopic ultrasonography, CT/MRI and other imaging.

4. Esophageal surgery experts believe that patients with potentially resectable esophageal cancer

5. No blood transfusion was received 3 months before enrollment;

6. ECOG PS score: 0-1.

Exclusion Criteria:

• Patients meeting any of the following criteria are not eligible for inclusion:

1. Women who are pregnant or breastfeeding;

2. previous or concurrent malignancy;

3. Participated in clinical trials of other drugs within four weeks;

4. Have a history of immune deficiency, or other acquired or congenital immune deficiency diseases, or have a history of organ transplantation, or have a history of serious chronic autoimmune diseases, such as systemic lupus erythematosus, etc.

5. Patients with hypersensitivity to human or mouse monoclonal antibodies;

6. Those who have a history of psychotropic drug abuse and cannot get rid of it or have mental disorders;

7. According to the judgment of the researcher, there are serious concomitant diseases that endanger the patient's safety or affect the patient's ability to complete the study.